Zipcode Bio
Zipcode Bio is a U.S.-based biotechnology company focused on next-generation nucleic acid therapeutics. The company develops organ-targeted delivery platforms for mRNA and oligonucleotide therapeutics, integrates machine learning into therapeutic design, and pursues preclinical development and collaborative programs including vaccine development and needle-free delivery approaches. Co-founders include Dr. Jason Zhang (CEO) and Dr. Drew Weissman.
Industries
N/A
Products
Single-component nanoparticle delivery platform (proprietary)
A single-component amphiphilic particle platform used to encapsulate and deliver nucleic acid therapeutics with organ-targeting properties (described for lung and spleen delivery).
Single-component nanoparticle delivery platform (proprietary)
A single-component amphiphilic particle platform used to encapsulate and deliver nucleic acid therapeutics with organ-targeting properties (described for lung and spleen delivery).
Services
Collaborative R&D and co-development
Joint research programs with external companies and research organizations to develop targeted delivery systems and therapeutic candidates.
Preclinical delivery optimization and evaluation
Design and testing of delivery formulations and in vivo evaluation of tissue targeting and initial safety/tolerability.
Collaborative R&D and co-development
Joint research programs with external companies and research organizations to develop targeted delivery systems and therapeutic candidates.
Preclinical delivery optimization and evaluation
Design and testing of delivery formulations and in vivo evaluation of tissue targeting and initial safety/tolerability.
Expertise Areas
- Nucleic acid therapeutics
- mRNA vaccine design
- Organ-targeted delivery systems
- Preclinical development
Key Technologies
- Single-component amphiphilic particle delivery
- Ionizable amphiphilic dendrimer-like formulations
- mRNA therapeutics
- Oligonucleotide therapeutics